Investigational Drug Information for Tegobuvir
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Tegobuvir?
Tegobuvir is an investigational drug.
There have been 5 clinical trials for Tegobuvir.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2011.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].
Summary for Tegobuvir
US Patents | 0 |
International Patents | 0 |
US Patent Applications | 280 |
WIPO Patent Applications | 192 |
Japanese Patent Applications | 102 |
Clinical Trial Progress | Phase 2 (2011-09-01) |
Vendors | 48 |
Recent Clinical Trials for Tegobuvir
Title | Sponsor | Phase |
---|---|---|
GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection | Gilead Sciences | Phase 2 |
GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection | Gilead Sciences | Phase 2 |
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection | Gilead Sciences | Phase 2 |
Clinical Trial Summary for Tegobuvir
Top disease conditions for Tegobuvir
Top clinical trial sponsors for Tegobuvir
US Patents for Tegobuvir
Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
---|---|---|---|---|
>Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |